Information and decision support tools for medicines
Found 636 result(s)
This page includes information on infection prevention and control (IPC) strategies for Candida auris (C. auris).
C. auris is a fungus (yeast) that is resistant to a range of antifungal medicines and can cause serious infections in patients who are immunocompromised. The severity, communicability, and drug resistance associated with C. auris infections means that correct identification and management of C. auris is crucial for the treatment and control of disease.
Clinical Care Standards describe the care that people can expect to be offered for a specific clinical condition, treatment, procedure or clinical pathway no matter where they are treated in Australia.
This page includes information on Clostridioides difficile infection (CDI) and reports on monitoring the burden of CDI in Australian hospitals.
The Commission's new Better Care Everywhere initiative will bring together the wide range of guidance, tools and resources developed by the Commission to provide a comprehensive approach to promoting appropriate and sustainable health care.
Indicators have been developed to support monitoring of the care recommended in the Sepsis Clinical Care Standard. Clinicians and healthcare services can use the indicators to support local quality improvement activities.
Getting the best outcomes for patients and reducing harm are the goals of the Atlas series. Each Atlas examines a series of health topics, investigates variation and the possible reasons for it, and provides specific achievable actions to reduce unwarranted variation.
Healthcare-associated Staphylococcus aureus bloodstream infection (SABSI) is commonly associated with significant morbidity and mortality. Resources to support prevention of these infections in health service organisations play an important role; information on strategies to support these activities, and access to a range of resources, are included on this page.
The National Medicines Symposium 2024, was held on the 19 November and explored the safe and appropriate use of medications in an ageing population.
The Commission is celebrating 10th years of Clinical Care Standards in Australia.
To mark this milestone in November 2024, clinicians and health services were invited to share their stories about successfully implementing one of our Clinical Care Standards and improvements in patient care. Submissions are now being reviewed and the best will be published by mid 2025.
Our Clinical Directors and Medical Advisors provide expert clinical advice on the wide range of programs managed by the Commission.
Guidance for clinicians on the seven quality statements from the Sepsis Clinical Care Standard, as well as helpful resources.
Effective infection prevention and control practices reduce the risk of transmission of infections between patients, healthcare workers and others in the healthcare environment.
Guidance for healthcare services on the ten quality statements from the COPD Clinical Care Standard, as well as helpful resources.
The rate of Staphylococcus aureus bloodstream infection (SABSI) in a hospital is considered to be an indication of the effectiveness of the hospital’s infection prevention and control program.
Several resources have been identified which are relevant for improving safe and appropriate use of medicines in an ageing population.
The Infection Prevention and Control (IPC) Advisory Committee provides a mechanism for the Commission to consult with experts and key stakeholders on the development and implementation of national initiatives related to IPC.
Based on advice, feedback and discussions with clinical experts and health services from across Australia, the Commission has compiled a list of FAQs and resources that may assist health services in the prevention and reduction of hospital-acquired complications (HACs).
Explore these resources and share your feedback.